TCM
NKTR icon

Teza Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Teza Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,333
Closed -$810K – 534
2020
Q2 		$810K Buy
+2,333
New +$728K 0.18% 168
2020
Q1 		– Sell
-3,853
Closed -$1.25M – 382
2019
Q4 		$1.25M Buy
+3,853
New +$1.12M 0.34% 60

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Teza Capital Management's NKTR Position: Q3 2020 in Review

Teza Capital Management sold out of Nektar Therapeutics (NKTR) in Q3 2020, closing a stake of 2,333 shares — an estimated $810K sold.

Teza Capital Management first reported a position in NKTR in Q4 2019 and held it in 2 quarters. The position peaked at $1.25M in Q4 2019. 249 funds tracked by Wall St. Rank hold NKTR as of Q3 2020.

  • Teza Capital Management reported no remaining Nektar Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Teza Capital Management sold 2,333 Nektar Therapeutics shares in Q3 2020, an estimated $810K.
  • Teza Capital Management first reported a position in Nektar Therapeutics in Q4 2019 and held it in 2 quarters.
  • Teza Capital Management's Nektar Therapeutics position peaked at $1.25M in Q4 2019.
  • 249 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2020.

Based on Teza Capital Management's 13F filing for Q3 2020, filed 12 Nov 2020.